Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Original Article
Author Details :
Volume : 4, Issue : 2, Year : 2018
Article Page : 209-212
https://doi.org/10.18231/2395-1451.2018.0046
Abstract
Purpose: To assess the efficacy and safety of sub-conjunctival bevacizumab in the management of grade II and III pterygium.
Materials and Methods: Cases of pterygium with no other ocular abnormality and with no systemic disorders were subjected to anterior segment photography and graded. Ten cases of grade III pterygium and eleven cases of grade II pterygium were administered subconjunctival intralesional injection of 2.5mg/0.1ml of bevacizumab. Anterior segment photographs were taken on day 7, day 28 and day 90 along with complete ocular examination and general physical examination. The pterygium vascularity, size and thickness were assessed keeping note of any adverse effects ophthalmic or otherwise. An evaluation of the symptoms before injection and at day 90 was also done.
Results: There was statistically significant improvement in the grade, color, intensity, size of pterygium, and symptoms of patients. There was a decrease in symptoms of redness, itching, watering, and irritation.
Of the 10 cases with Grade III on enrollment, 08 (80%) had shown a decrease in vascularity with half of them graded as II and the remaining half as grade I.
Of the 11 cases of Grade II pterygium at baseline, 05 (45%) cases changed to grade I by day 90.
Conclusion: This study revealed that the sub-conjunctival injection of bevacizumab was found to be useful in reduction of symptoms of patients with grade III & II pterygium with no local or systemic adverse effects.
Keywords: Bevacizumab, Pterygium, Subconjuctival, Treatment.
How to cite : Pathania M, Gurunadh V, Khan M, Efficacy and safety of subconjuctival bevacizumab injection in the management of pterygium. Indian J Clin Exp Ophthalmol 2018;4(2):209-212
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.